All News
Depends on Where You’re Looking (8.9.2024)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.
Read Article
Breast CA (BC) & TNFi - study of 2 cohorts (Optum commercial * SEER/Medicare) found that 17% & 16% of BC pts received TNFi. 1 yr overall survival was no different +/- TNFi (HR= 0.77 & 0.84); but BC survival better on TNFi (HR 0.28; 0.08–0.98) vs csDMARDs. https://t.co/cGqT80rGTR https://t.co/n7i5VNFkVT
Dr. John Cush RheumNow ( View Tweet)
Oral microbiota study (w/ 16S rRNA sequencing) of 72 severe psoriasis vs 16 controls. PsA pts had incr in Aggregatibacter & decr Prevotella. PsO pts had incr in Capnocytandophaga, Campylobacter & Acetobacter, but decr Bacteroides & Muribaculaceae https://t.co/ol947Afupt https://t.co/OknMRtJ4oT
Dr. John Cush RheumNow ( View Tweet)
Prescription Painkiller Misuse in Chronic Pain Patients
A new scientific review has found that nearly 1 in 10 patients experiences opioid dependence or opioid use disorder and nearly 1 in 3 shows symptoms of dependence and opioid use disorder.
https://t.co/DnUe1l51bS https://t.co/G4RPg8eqqe
Dr. John Cush RheumNow ( View Tweet)
Review of Inflammatory vs non-inflammatory pain in RA
- Pain may be more than inflammation
- Residual plain is a problem
- Consider damage vs FM
- Central vs. Neuogenic pain https://t.co/JUgc5IsgMq https://t.co/CRekJsAP04
Links:
Dr. John Cush RheumNow ( View Tweet)
Lit review of ILD in anti-synthetase syndrome finds no conclusive evidence of effective treatment. 10 studies, 514 pts (68% female); Hi Res CT positive in 87% w/ 49% having NSIP pattern. 48% Jo-1+, 28% Ro52+. Low improvements w/ RTX (12%), CYC (17%). https://t.co/B7R0xQrUyw https://t.co/2hMzO8hyiV
Dr. John Cush RheumNow ( View Tweet)
Retrospective study from Univ of Tokyo on 194 Behcets dz (BD) pts, found 25% who developed intestinal BD (meanF/U 12 yrs). Use of #PPI significantly incr risk of intestinal BD (adj HR 2.48; vs non-PPI), w/ a confirmed duration/dose-dependent relationship. https://t.co/qFeS8svMLj https://t.co/KT8OBrY96S
Dr. John Cush RheumNow ( View Tweet)
Immune pathology of bursitis in rheumatic conditions - role of inflammation, degeneration, & mechanical stress. Cells and cytokines involved. Tenditis and tenosynovitis often coexist w/ bursitis https://t.co/fXf1LBTS4e https://t.co/LxmsIXhZaU
Links:
Dr. John Cush RheumNow ( View Tweet)
Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy. 92% female, median age 56yrs w/ very hi CK levels, 31% have overlap w/ scleroderma (half of these have ILD). Path shows by myofiber necrosis, MHC-class I/II+, endomysial inflammation https://t.co/7HDUEPmbdi https://t.co/vnSjOph31G
Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA: Trends in the Ranking of Leading Causes of Death—US, 2019-2023 https://t.co/RgGrYe0tbE https://t.co/SdMmadOD3S
Dr. John Cush RheumNow ( View Tweet)
3+ million persons died in USA in 2023. Overall age-adjusted death rate in 2023 was 6.1% lower than 2022. Overall death rate highest among non-Hispanic Blacks or African Americans. The number of COVID-19 deaths was 68.9% lower than in 2022 https://t.co/Oqgxcs4yUz https://t.co/lDn1PuEQ5Z
Dr. John Cush RheumNow ( View Tweet)
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA.
https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj
Dr. John Cush RheumNow ( View Tweet)
Relapses with RTX Maintenance in ANCA-associated Vasculitis
A real-world study on ΜPA and GPA patients found that RTX maintenance had a 25% relapse risk, with lower rates when combined with cyclophosphamide treatment.
https://t.co/bD6u5JWVqS https://t.co/CSotJt4in1
Dr. John Cush RheumNow ( View Tweet)
Study of 4378 pts COVID tested betw 2020-22, found low risk (3-4%)of myalgic encephalomyelitis/chronic fatigue syndr (ME/CFS) subsequent to SARS-CoV-2 infx, w/ no difference betw COVID test pos & neg. (OR 0.84; 0.42-1.67) Not supporting long COVID as FM? https://t.co/M0NWvuxT2n https://t.co/hoW5sVOYcN
Dr. John Cush RheumNow ( View Tweet)
Exploratory study of 22 RA pts w/ mod/severe periodontitis and RA. After periodontal Tx, only pts w/ severe (not moderate) periodontitis had significant reduction in DAS28 and CCP2 levels. Use periodontal Tx in RA management & T2T strategy? https://t.co/X7oXByzTnX https://t.co/b0vwTp4tfd
Dr. John Cush RheumNow ( View Tweet)
EU study of 1052 systemic sclerosis pts failed to show early immunosuppressive use (vs late) lowered ILD risk. Early Rx (Dz Dur < 3yrs) group (n=547, 52%) more male, diffuse Dz, 60% Rx w/ MTX (1.7% biologics); ILD in 47% after3.6yrs (HR 1.13;0.93–1.38) https://t.co/PtQlgyX0TE https://t.co/R7X3zvPvIg
Dr. John Cush RheumNow ( View Tweet)
Tick-borne diseases have increased in the last decade in the US, including Lyme disease (~476 000/yr), babesiosis, human granulocytic anaplasmosis (HGA), Rocky Mountain spotted fever, monocytic ehrlichiosis (HME), alpha gal allergy (red meat allergy) https://t.co/tl8qPyjU3Z https://t.co/AP0wglsJXM
Dr. John Cush RheumNow ( View Tweet)
The adipokine Resistin - predicts disease severity and survival in patients with pulmonary arterial hypertension. High resistin levels (>4.5ng/mL) in PAH assoc w/ older age, shorter 6-min walk, decr CV performance, incr death (HR 2.6) https://t.co/TUR4KnVsR9 https://t.co/rc6IMNWH4w
Dr. John Cush RheumNow ( View Tweet)
Prospective Vasculitis Study of Takayasu’s Arteritis - 236 pts, 92% women, mean age 36 yrs, Dz duration 2.6yrs. Damage present in >80% at baseline (75% vascular, 40+% cardiac), even with recent Dx and >40% pts accrue new, mainly disease-specific damage https://t.co/DKZQdH4HuZ https://t.co/LVjqAZYnOZ
Dr. John Cush RheumNow ( View Tweet)